Denosumab, a human-derived monoclonal antibody targeting RANKL, competes with RANK on the osteoclast surface for RANKL binding, effectively and safely inhibiting bone resorption and reducing the risk of SREs in postmenopausal women with osteoporosis and bone metastasis from multiple myeloma or breast cancer [179,180]. This evidence concerns the gene TNFSF11 and osteoporosis.